PTGX · Protagonist Therapeutics, Inc.
$138.43
-0.79% last session
End-of-day data · close of 2026-10-23
Market cap
$9B
Enterprise value
$8B
Trailing P/E
134.4
Forward P/E
-1,394.6
Dividend yield
0.0%
Beta
1.52
Avg volume
1M
Employees
0K
Daily Change %
-0.79%
5 Days Change
8.37%
10 Days Change
0.75%
30 Days Change
0.60%
60 Days Change
-9.82%
Month to Day Change
0.24%
Year to Day Change
59.75%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PTGX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
UBS
Buy$184
+32.9% vs priceBarclays
Overweight$180
+30.0% vs priceCitigroup
Buy$182
+31.5% vs priceGoldman Sachs
Buy$186
+34.4% vs priceJP Morgan
Overweight$106
-23.4% vs priceJefferies
Buy$118
-14.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Maintains | Buy | $155 → $160 |
| 2026-10-12 | UBS | Initiates | Buy | $0.00 → $184 |
| 2026-09-01 | Barclays | Maintains | Overweight | $153 → $180 |
| 2026-09-01 | BMO Capital | Maintains | Outperform | $178 → $190 |
| 2026-08-31 | Citigroup | Maintains | Buy | $175 → $182 |
| 2026-08-31 | HC Wainwright & Co. | Maintains | Buy | $167 → $170 |
| 2026-08-17 | BMO Capital | Maintains | Outperform | $112 → $178 |
| 2026-08-10 | Truist Securities | Maintains | Buy | $145 → $170 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 4.0% below the 50-day MA ($144.21).
- bullish: Price vs 200-day MA: Trading 20.3% above the 200-day MA ($115.09).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.18) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($73.99) and high ($158.62).
PTGX Price Chart
Loading chart for PTGX…
Fundamentals
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.